Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | MMP12 | P39900 | 1/20 | 0.43 |
| ▸ | MMP13 | P45452 | 1/20 | 0.43 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.43 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.42 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.42 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.42 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7199571 | 1.00 | NPC1 (0.46) | NPC1RAB9AALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL2219303 | 0.78 | SLC1A3 (0.60) | NPC1RAB9ASMN1; SMN2KDM4ETSHR | |
| SCHEMBL2219306 | 0.78 | SLC1A3 (0.60) | NPC1RAB9ASMN1; SMN2KDM4ETSHR | |
| SCHEMBL1712557 | 0.78 | SLC1A3 (0.60) | NPC1RAB9ASMN1; SMN2KDM4ETSHR | |
| SCHEMBL22310130 | 0.75 | TSHR (0.54) | NPC1RAB9AALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL28946733 | 0.74 | ALDH1A1 (0.58) | NPC1RAB9AALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL27513910 | 0.74 | TSHR (0.55) | NPC1RAB9AALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL24503039 | 0.73 | CTSC (0.46) | NPC1RAB9AALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL16075210 | 0.73 | CTSC (0.46) | NPC1RAB9AALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL7195015 | 0.73 | GPR84 (0.60) | NPC1RAB9AALDH1A1SMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030198598-A1 | Polypeptide derivatives | ALBERT RAINER (CH) | 2003-10-23 | — | — | US | claimed |
| EP-0436005-B1 | LABELED POLYPEPTIDE DERIVATIVES | SANDOZ LTD (CH) | 1995-03-29 | — | — | EP | claimed |
| US-5116817-A | LHRH preparations for intranasal administration | SYNTEX (U.S.A.) INC. (US) | 1992-05-26 | — | — | US | claimed |
| EP-0436005-A1 | LABELED POLYPEPTIDE DERIVATIVES. | SANDOZ LTD (CH) | 1991-07-10 | — | — | EP | claimed |
| WO-1991001144-A1 | LABELED POLYPEPTIDE DERIVATIVES | SANDOZ LTD (CH) | 1991-02-07 | — | — | WO | claimed |
| WO-1989009786-A1 | PEPTIDE DERIVATIVES | SANDOZ AG (CH) | 1989-10-19 | — | — | WO | claimed |
| EP-0097031-B1 | NONAPEPTIDE AND DECAPEPTIDE ANALOGS OF LHRH USEFUL AS LHRH ANTAGONISTS, THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM | SYNTEX (U.S.A.) INC. (US) | 1988-09-21 | — | — | EP | claimed |
| EP-0111841-B1 | LHRH PREPARATIONS FOR INTRANASAL ADMINISTRATION | SYNTEX (U.S.A.) INC. (US) | 1987-05-06 | — | — | EP | claimed |
| EP-0111841-A1 | LHRH preparations for intranasal administration | SYNTEX (U.S.A.) INC. (US) | 1984-06-27 | — | — | EP | claimed |
| EP-0097031-A2 | Nonapeptide and decapeptide analogs of LHRH useful as LHRH antagonists, their preparation and compositions containing them | SYNTEX (U.S.A.) INC. (US) | 1983-12-28 | — | — | EP | claimed |
| US-20030198598-A1 | Polypeptide derivatives | ALBERT RAINER (CH) | 2003-10-23 | — | — | US | disclosed |
| US-5686410-A | EPIDERMAL GROWTH FACTOR WITH CHELATING GROUP | NOVARTIS AG (CH) | 1997-11-11 | — | — | US | disclosed |
| US-5541159-A | PEPTIDE HORMONE ANTAGONIST | SANDOZ LTD. (CH) | 1996-07-30 | — | — | US | disclosed |
| EP-0436005-B1 | LABELED POLYPEPTIDE DERIVATIVES | SANDOZ LTD (CH) | 1995-03-29 | — | — | EP | disclosed |
| EP-0312052-B1 | Intranasal administration of polypeptides in powdered form | SYNTEX INC (US) | 1994-01-05 | — | — | EP | disclosed |
| EP-0097031-B1 | NONAPEPTIDE AND DECAPEPTIDE ANALOGS OF LHRH USEFUL AS LHRH ANTAGONISTS, THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM | SYNTEX (U.S.A.) INC. (US) | 1988-09-21 | — | — | EP | disclosed |
| EP-0111841-B1 | LHRH PREPARATIONS FOR INTRANASAL ADMINISTRATION | SYNTEX (U.S.A.) INC. (US) | 1987-05-06 | — | — | EP | disclosed |
| EP-0111841-A1 | LHRH preparations for intranasal administration | SYNTEX (U.S.A.) INC. (US) | 1984-06-27 | — | — | EP | disclosed |
| EP-0097031-A2 | Nonapeptide and decapeptide analogs of LHRH useful as LHRH antagonists, their preparation and compositions containing them | SYNTEX (U.S.A.) INC. (US) | 1983-12-28 | — | — | EP | disclosed |
| EP-0097031-A2 | Nonapeptide and decapeptide analogs of LHRH useful as LHRH antagonists, their preparation and compositions containing them | SYNTEX (U.S.A.) INC. (US) | 1983-12-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030198598-A1 | Polypeptide derivatives | HDGF, IGFBP1, VIP | NPC1 4417/4885RAB9A 3466/4885ALDH1A1 4768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.